I'll Len. up pick you you, the left story. me Thank REGEN-COV where with
from States, In involving REGEN-COV XX,XXX potential also to EUA to for prophylaxis provided under mentioned, to full that compelling currently certain the Regeneron, But vaccination April prevention research evidence has all appreciate reviewed is we is as with to best widespread possible in XXXX. action broadly REGEN-COV the and Len an has patients from various treating date as an and COVID-XX. being way protect many of people of At recent XX, coverage particularly in hospitalized date the some As be the treatment States million and people alone of COVID-XX the pre-exposure important approval provided in vulnerable, leaving more remain robust that immunocompromised the development United authorized patients. our vaccines, COVID-XX FDA the United also for used for treatment several the individuals applications some people prevention prisoners who than pandemic. by program uniquely gaps reveals
to First, or at vaccination, even population respond not shots. all after booster the many of immunocompromised sub-optimally
the that Second, people breakthrough within and will individuals also Therefore, people for continue data extended chronic and a authorization to certain and we vaccination, population most a to the unprotected of immunosuppressive to cancers, in infected United REGEN-COV Regeneron's prevention REGEN-COV population, individuals the we COVID-XX be of prophylaxis developing infections and of particular began for still In certain to in with be meaning severe April. immunocompromised, rheumatoid optimize commitment transplant after risk diseases even importance highest This arthritis, use population. as disease. primary evaluation that believe remain myeloma expand occur organ who these for Further sclerosis, encountering multiple to risk immunocompromised could this to REGEN-COV immunocompromised at include back trial vaccinated at of the emergency in highly submitted big with reflecting recently example, in including for FDA dose. includes for lymphomas, for leukemias immunodeficiencies. the take existing Regeneron who recipients hematologic medicines request those the such general and people States, are a
of against variant. Our all activity known cocktail interest, potent Delta variants current REGEN-COV including retains the
discussed, advancing anti-spike However, evolve. mutate into the have are development. a and we clinical thus, cocktail previously antibody virus protein novel continues as And to we
in as proactively that potency novel in done the potential against have required antibody of cocktail retains new variants We case a the so innovative future.
the high-dose Phase dose CANDELA XX higher in We approved patients EYLEA X-milligram AMD. dosing at proof-of-concept to in dose week the results III proportion Phase X-milligram XX. study the currently half dose of a and in the patients III XX in aflibercept. are comparison will Ophthalmology. every the group primary its overall signals currently of wet understanding report are were fully convenience of had to endpoint, The the efficacy DME, Phase EYLEA treated and weeks of aflibercept line AMD evaluating encouraging data to of large to in expected to safety aflibercept and X-milligram retinal data in no met and trials high These of approved in intervals XXXX. study small be dose, safety the observed reported with Moving every fluid top no efficacy, weeks second crucial There enrolled compared X aflibercept high wet II
asthma hypothesis long-standing clinical all that these The or across inflammatory many of success same the tract. Dupixent. interleukin-XX which interleukin-X the in the by esophagitis or as with immunologic validates Dupixent remarkable GI in early to X effectively Dupixent in and so polyps allergic of the is type disease whether overactivation or nodularis on fundamental and the are airways nasal as rhinositis diseases, the by conditions as chronic atopic pathway, prurigo skin, pathway is Moving driven blocked eosinophilic the dermatitis our manifests different that
Dupixent and data as rate as that dermatitis be a the the of data million placebo. observed impact the trial an this Detailed lower seem important will on have from compared skin months this children vision This of of news months, group only studies. In will suffering reinforce atopic not type initially well did Dupixent it's In medical age, clinical and profile results year. pivotal X infections of of met related. Dupixent treated is and to great demonstrated a Our these all future patients separate submitted positive FDA the with our a endpoints dedication recent results conditions from past few stemming diseases. Dupixent efficacy trial young These meeting, at and date. accomplishment secondary demonstrated safety as in Dupixent from and these and team end the in the a to X many of Phase be inflammatory data in patients over in by as III X.X X infants to well-established presented for tremendous primary
patients update patients in progressive reported of our to they the dilation disease Phase this a also to questionnaire, United so X/X XX-point which of the Dupixent the approximate Completion placebo. improvement the XXXX XX XX-week EoE, in the our data EoE damages with had Week that Gastroenterology improvement reinforced our impairs results the Virtual improvement a We recently early III for Dupixent had previously and More esophagus and than planned trial adolescents study, the relief. endoscopic compared eosinophilic This XX% recent for to dysphagia previously filing XXXX. for Congress. follow-up is in were to that for reported swallow. on ability a of undergo esophagitis III for X of symptom disease adults regulatory severe esophagus XX-point manifestations symptomatic weekly representing results at had In European taking an presented or Phase
planned yet nodules. also first an The enrolled 'XX prurigo placebo, submissions and and fully achieving in reported quality from the nodularis, Dupixent expected by and of the second baseline same half primary known trial positive out and and to condition is characterized of from in III life. A at skin read recently improvement met regulatory prurigo another in trial for We including endpoints year. with nodularis is in in data Dupixent type trial including would exciting itch approved XX X approvals, months. or its these as XX results to X reduction all key indications, X our regulatory for secondary for in If as to young clear Phase all underdiagnosed skin allergic inflammatory weeks, patients Phase inflammatory disease comparison as lead be different extreme III skin itch disease
Libtayo Libtayo chemotherapy These at that both studies presented lung mark irrespective in Libtayo PD-X cell first Phase in in positive Positive were ESMO meeting. as clinical of data Oncology. first-line as or cell X XXXX included non-small a characteristics demonstrate disease These with with that everyday in difficult-to-treat practice. to advanced combination of non-small to III inhibitors conducted combination III chemotherapy. reflects data results X Moving population in Libtayo lung Phase were and monotherapy line histology, only PD-LX of cancer patient the cancer, in
opportunity progressing rapidly which across population patients. expression the are an for a larger PD-LX of to cancer could histologies towards unlock and help We regulatory levels, Libtayo submission lung chemotherapy combination
portfolio. of of REGNXXXX. At we to our a presentation updates data American Hematology. will our provide upcoming developing registrational Meeting The ASH, for trial the to potentially Turning Annual Hematology Society provide will first-in-human Hematology we for update nodal
of utility Our pretreated in prior major antibody be bispecific a BCMA myeloma. have our not treatment tested several of to limited patients population. BCMA-targeted lines by therapy, CDX failed this patients bispecific heavily is advance REGNXXXX but who potential with of to multiple patient in the
bispecific. event CDXX or scheduled plans Monday, We at our will ASH discuss regarding further and December virtual our XX development data for odronextamab Investor by CDX
are our trial with start We to this since track in -- odronextamab pivotal recruitment the of is year. pleased our formulation end was clinical potentially hall by year. partial with of earlier lifted Exploration this of the on subcutaneous
planning Phase programs are III We in to XXXX. initiate broader
development as including monotherapy tumors solid in ovarian MUCXXxCDXX MUCXXxCDX as with our for unique costim. with or our combination approaches, is well program in progressing bispecific bispecific Our Libtayo the cancer as with
with to expect addition, in we In costim prostate in with our initial 'XX. have data patients PSMAxCDXX cancer
for clinical costim EGFRxCDXX excited as antibody EGF cancer our our drug We METxMET conjugate, lung of stage the clinical phase multiple conjugates including we drug for our bispecific well important program settings, potentially as class Regeneron. realm a about new and Oncology, cancer our best METxMET presenting high conclusion linked are Regeneron antibodies. also across into to for in bispecific In approaching are new [indiscernible] an
We in have the more Phase programs coming several expected clinical months. novel development in I/II with
to pembrolizumab planned Regeneron for in Hematology/Oncology bring in monotherapy well our updates. have would Libtayo with that investments such collaboration the genetics our We conclude advanced against potential first-line like programs our the may to I large for these as melanoma III excited also about as patients. registrational large our We're important our portfolio studies LAG-X medicines Phase as bispecifics. comparator
and from of medicine emerging genetics uniquely findings products positioned are our to established our efforts. biologics portfolio We combine
Alnylam, collaboration looking multiple program. As our part we updates on of our are CX to forward with
with As we siRNA, data meeting, our already for CX mentioned show CX ASH we combination antibody, first-in-human will in cemdisiran. inhibiting pozelimab the
the protein on CX or We regimen nocturnal CX complete therapeutic. Early will necessary breakthrough providing a combination mediated extended provide resulting antibody which healthy is target the this of siRNA which complement volunteers, lower complete and less [indiscernible] supports convenient monotherapy hematuria. did patients achieve PNH a while could present results dosing for inhibition, an terminal paroxysmal therapy of initial and data disease adequate dose in control not blockade, specific development antibody for in an efficacy hemolysis. first-of-its-kind better more same Adding in and with more siRNA
We have also testing recently myasthenia siRNA CX combination gravis. initiated a the Phase III antibody study and in
the tested for the test genetic For discoveries to show and approach potential stage we NASH, therapies, reaching of options finding using this our has naive have both gene where approach PNH, clinical liver a combo a care are combination the has treatment to we switch next are been with of of standard a in protective of Recall, collaboration starting of disease a some including we compelling This the target a target. HSDXXBXX the with variant difficult. lower XX% chronic our disease. of discovered for nonalcoholic Also steatohepatitis We're or planning that Alnylam, and as identified patients readouts to disease. true people ravulizumab potential benefit XX% year, gene siRNA to eculizumab. the against study silence treatment in odds initial
healthy initial their at show later this the will upcoming targeting R&D volunteer Alnylam, HSD, HSDXXBXX collaborator, Day the data month. siRNA Alnylam safety for Our
diseases and could I to with describes be potential diabetes, turn call such drug the first asthma others. manuscript for Finally, Biobank almost U.K. the from paper sequencing in the in achievement X.X of nature, milestone October, Regeneron which This the for genes exomes And will Marion. a Center million Genetics over that, that database. published the rare of targets time variants hypertension, of highlighted nature as
